Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.
On 30 June 2010, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £11.37 per Ordinary share and $34.05 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2010 to 30 June 2010:
Non Executive Director |
Ordinary Shares |
American Depository Shares (ADSs) |
|
|
|
Sir Christopher Gent |
2,968.34 |
|
|
|
|
Prof. Sir Roy Anderson |
577.18 |
|
|
|
|
Dr Stephanie Burns |
|
809.11 |
|
|
|
Mr Lawrence Culp |
|
1,618.22 |
|
|
|
Sir Crispin Davis |
2,088.83 |
|
|
|
|
Sir Deryck Maughan |
|
1,618.22 |
|
|
|
Mr James Murdoch |
1,649.08 |
|
|
|
|
Dr Daniel Podolsky |
|
1,483.36 |
|
|
|
Mr Tom de Swaan |
852.02 |
|
|
|
|
Sir Robert Wilson |
577.18 |
|
The Company and the Non-Executive Directors were informed of these allocations on 1 July 2010.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
1 July 2010